Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T85435
|
||||
Former ID |
TTDS00292
|
||||
Target Name |
Insulin receptor
|
||||
Gene Name |
INSR
|
||||
Synonyms |
CD220 antigen; IR; INSR
|
||||
Target Type |
Successful
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Alzheimer disease [ICD9: 331; ICD10: G30] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Crohn's disease [ICD9: 555; ICD10: K50] | |||||
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | |||||
Hypoglycemia [ICD9: 250.8, 251.0, 251.1, 251.2, 270.3, 775.6, 962.3; ICD10: E16.0-E16.2] | |||||
Hunter syndrome [ICD10: E76.1] | |||||
Hyperlipidaemia [ICD9: 272.0-272.4; ICD10: E78] | |||||
Hyperglycaemia in type 2 diabetes [ICD9: 250, 790.29; ICD10: E11, R73.9] | |||||
Hypercholesterolemia [ICD10: E78] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Non-insulin dependent diabetes [ICD10: E11.9] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Type 1 diabetes [ICD9: 250; ICD10: E10] | |||||
Type 1/2 diabetes [ICD9: 250, 278; ICD10: E08-E13] | |||||
Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
Function |
Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src- homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti- apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K- AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T85435
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.10.1
|
||||
Sequence |
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN PS |
||||
Drugs and Mode of Action | |||||
Drug(s) | Insulin Lispro | Drug Info | Approved | Diabetes | [1], [2] |
Insulin Lyspro recombinant | Drug Info | Approved | Diabetes | [3] | |
Insulin recombinant | Drug Info | Approved | Diabetes | [3] | |
Insulin, porcine | Drug Info | Approved | Diabetes | [3] | |
Insulin-glulisine | Drug Info | Approved | Diabetes | [4] | |
Insulin-lispro | Drug Info | Approved | Diabetes | [3] | |
Meglitinides | Drug Info | Approved | Hyperglycaemia in type 2 diabetes | [5] | |
Metformin arginine-hemisuccinimide | Drug Info | Approved | Type 2 diabetes | [6] | |
Ryzodeq | Drug Info | Approved | Type 2 diabetes | [7] | |
NN5401 | Drug Info | Phase 3 | Diabetes | [8] | |
Metformin glycinate | Drug Info | Phase 2/3 | Type 2 diabetes | [9] | |
DM-71 | Drug Info | Phase 2 | Type 2 diabetes | [10] | |
DM-99 | Drug Info | Phase 2 | Alzheimer disease | [11] | |
EGS-21 | Drug Info | Phase 2 | Crohn's disease | [12] | |
Mitoglitazone | Drug Info | Phase 2 | Type 2 diabetes | [13] | |
MSDC-0602 | Drug Info | Phase 2 | Type 2 diabetes | [14] | |
NP-01 | Drug Info | Phase 2 | Type 2 diabetes | [15] | |
S-707106 | Drug Info | Phase 2 | Type 2 diabetes | [16] | |
TAK-379 | Drug Info | Phase 2 | Type 2 diabetes | [17] | |
Tesofensine | Drug Info | Phase 2 | Pain | [18] | |
VVP-808 | Drug Info | Phase 2 | Type 2 diabetes | [19] | |
DM-199 | Drug Info | Phase 1/2 | Autoimmune diabetes | [20] | |
Insulin oral sublingual | Drug Info | Phase 1 | Type 1 diabetes | [21] | |
Insulin transdermal | Drug Info | Phase 1 | Type 1/2 diabetes | [22] | |
ISF-402 | Drug Info | Phase 1 | Type 2 diabetes | [23] | |
NN-1218 | Drug Info | Phase 1 | Diabetes | [24] | |
AKP-020 | Drug Info | Discontinued in Phase 2 | Type 2 diabetes | [25] | |
DM-83 | Drug Info | Discontinued in Phase 2 | Type 2 diabetes | [26] | |
EML-336 | Drug Info | Discontinued in Phase 2 | Type 2 diabetes | [27] | |
KW-2450 | Drug Info | Discontinued in Phase 1/2 | Breast cancer | [28] | |
CLX-0900 | Drug Info | Terminated | Hyperlipidaemia | [29] | |
TER-16998 | Drug Info | Terminated | Diabetes | [30] | |
Inhibitor | 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol | Drug Info | [31] | ||
4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol | Drug Info | [31] | |||
Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate | Drug Info | [32] | |||
compound 15 | Drug Info | [33] | |||
GSK-1838705A | Drug Info | [34] | |||
Metformin arginine-hemisuccinimide | Drug Info | [35] | |||
Metformin glycinate | Drug Info | [36] | |||
NVP-AEW541 | Drug Info | [37] | |||
NVP-TAE684 | Drug Info | [38] | |||
Tesofensine | Drug Info | [39] | |||
VVP-100X | Drug Info | [40] | |||
Agonist | AD10-1025 | Drug Info | [40] | ||
DM-199 | Drug Info | [40] | |||
DM-99 | Drug Info | [40] | |||
NP-01 | Drug Info | [40] | |||
Enhancer | AKP-020 | Drug Info | [41] | ||
Modulator | CLX-0900 | Drug Info | [42] | ||
DC-9703 | Drug Info | [40] | |||
DM-71 | Drug Info | [40] | |||
EGS-21 | Drug Info | [43] | |||
EML-336 | Drug Info | [40] | |||
FPT-038 | Drug Info | [40] | |||
Insulin oral sublingual | Drug Info | [40] | |||
Insulin transdermal | Drug Info | [44] | |||
ISF-402 | Drug Info | [45] | |||
KW-2450 | Drug Info | [46] | |||
Mitoglitazone | Drug Info | [47] | |||
MSDC-0602 | Drug Info | [48] | |||
NN-1218 | Drug Info | [49] | |||
NN5401 | Drug Info | [40] | |||
Quick-acting insulin | Drug Info | [40] | |||
RHIIP | Drug Info | [50] | |||
Ryzodeq | Drug Info | [40] | |||
S-707106 | Drug Info | [40] | |||
TAK-379 | Drug Info | [40] | |||
VVP-808 | Drug Info | [40] | |||
Stimulator | DM-83 | Drug Info | [40] | ||
Meglitinides | Drug Info | [5] | |||
Binder | Humulin (Human insulin isophane) | Drug Info | [51] | ||
Insulin Lispro | Drug Info | [52] | |||
Insulin Lyspro recombinant | Drug Info | [51] | |||
Insulin recombinant | Drug Info | [51] | |||
Insulin, porcine | Drug Info | [53] | |||
Insulin-glulisine | Drug Info | [54] | |||
Insulin-lispro | Drug Info | [52] | |||
Activator | TER-16998 | Drug Info | [40] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
DRM | DRM Info | ||||
Pathways | |||||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
cGMP-PKG signaling pathway | |||||
HIF-1 signaling pathway | |||||
FoxO signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
AMPK signaling pathway | |||||
Adherens junction | |||||
Insulin signaling pathway | |||||
Ovarian steroidogenesis | |||||
Type II diabetes mellitus | |||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Aldosterone-regulated sodium reabsorption | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PANTHER Pathway | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | ||||
Insulin/IGF pathway-protein kinase B signaling cascade | |||||
PI3 kinase pathway | |||||
Pathway Interaction Database | Insulin Pathway | ||||
Signaling events mediated by PTP1B | |||||
Signaling events mediated by TCPTP | |||||
Insulin-mediated glucose transport | |||||
PathWhiz Pathway | Insulin Signalling | ||||
Leucine Stimulation on Insulin Signaling | |||||
Reactome | IRS activation | ||||
Signal attenuation | |||||
Insulin receptor signalling cascade | |||||
Insulin receptor recycling | |||||
WikiPathways | DNA Damage Response (only ATM dependent) | ||||
Insulin Signaling | |||||
Nanoparticle triggered autophagic cell death | |||||
AGE/RAGE pathway | |||||
Signaling by Insulin receptor | |||||
Folate Metabolism | |||||
Type II diabetes mellitus | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
AMPK Signaling | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002887) | ||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
REF 4 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | ||||
REF 5 | New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68(15):2131-62. | ||||
REF 6 | Clinical pipeline report, company report or official report of Boehringer Ingelheim Pharmaceuticals. | ||||
REF 7 | Clinical pipeline report, company report or official report of Novo nordisk. | ||||
REF 8 | ClinicalTrials.gov (NCT01059812) A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes. U.S. National Institutes of Health. | ||||
REF 9 | ClinicalTrials.gov (NCT00940472) Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients. U.S. National Institutes of Health. | ||||
REF 10 | Clinical pipeline report, company report or official report of DiaMedica Inc. | ||||
REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030024) | ||||
REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020751) | ||||
REF 13 | ClinicalTrials.gov (NCT01103414) Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients. U.S. National Institutes of Health. | ||||
REF 14 | ClinicalTrials.gov (NCT01280695) A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients. U.S. National Institutes of Health. | ||||
REF 15 | Clinical pipeline report, company report or official report of Medesis Pharma SA. | ||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031641) | ||||
REF 17 | ClinicalTrials.gov (NCT00722917) Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | ||||
REF 18 | ClinicalTrials.gov (NCT00153010) An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type. U.S. National Institutes of Health. | ||||
REF 19 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029155) | ||||
REF 20 | ClinicalTrials.gov (NCT01845064) A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients. U.S. National Institutes of Health. | ||||
REF 21 | Clinical pipeline report, company report or official report of Biodel. | ||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024972) | ||||
REF 23 | Clinical pipeline report, company report or official report of Dia-B Tech. | ||||
REF 24 | ClinicalTrials.gov (NCT01121289) A Trial Investigating NN1218 in Subjects With Type 1 Diabetes. U.S. National Institutes of Health. | ||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026051) | ||||
REF 26 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030050) | ||||
REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016521) | ||||
REF 28 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030562) | ||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013573) | ||||
REF 30 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007187) | ||||
REF 31 | Eur J Pharmacol. 2007 May 7;562(1-2):1-11. Epub 2007 Feb 3.ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. | ||||
REF 32 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
REF 33 | Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8. | ||||
REF 34 | GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. | ||||
REF 35 | Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91. | ||||
REF 36 | Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144. | ||||
REF 37 | J Med Chem. 2009 Aug 27;52(16):4981-5004.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. | ||||
REF 38 | Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21.Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | ||||
REF 39 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. | ||||
REF 40 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). | ||||
REF 41 | Effect of vanadium on insulin and leptin in Zucker diabetic fatty rats. Mol Cell Biochem. 2001 Feb;218(1-2):93-6. | ||||
REF 42 | CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3. | ||||
REF 43 | Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 2014 Jan 10;289(2):723-34. | ||||
REF 44 | Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461-74. | ||||
REF 45 | Ability of GHTD-amide and analogs to enhance insulin activity through zinc chelation and dispersal of insulin oligomers. Peptides. 2009 Jun;30(6):1088-97. | ||||
REF 46 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
REF 47 | An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73. | ||||
REF 48 | Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. | ||||
REF 49 | Ultrafast-Acting Insulins: State of the Art. J Diabetes Sci Technol. 2012 July; 6(4): 728-742. | ||||
REF 50 | PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab. 2009 May;11(5):455-9. | ||||
REF 51 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
REF 52 | Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2. | ||||
REF 53 | Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9. | ||||
REF 54 | Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. doi: 10.2165/00003495-200969080-00006. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.